Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome.
Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome.
复制标题
DOI：
10.1016/j.tips.2017.01.005
复制
发表时间：
2017-04
影响因子：
13.8
通讯作者：
Rhee KY
中科院分区：
文献类型：
--
作者：
Jansen RS;Rhee KY
结核病化疗曾经被认为是现代药物开发的最高成就，但事实证明，它越来越无法跟上大流行的蔓延和耐药性上升的步伐。与此同时，重振结核病药物开发渠道的努力却步履蹒跚。更仔细的分析揭示了关键的实验缺陷，这些缺陷阻碍了我们将抗生素机制知识“逆向工程”到合理药物开发的能力。在这里，我们讨论代谢组学（小分子代谢物的系统水平研究）的新兴潜力，以帮助克服这些差距并充当化合物表型特性和生物靶标之间独特的生化桥梁。
Once considered a crowning achievement of modern drug development, tuberculosis (TB) chemotherapy has proven increasingly unable to keep pace with the spread of the pandemic and rise of drug resistance. Efforts to revive the TB drug development pipeline have, in the meantime, faltered. Closer analysis reveals key experimental deficiencies that have hindered our ability to ‘reverse engineer’ knowledge of antibiotic mechanism into rational drug development. Here, we discuss the emerging potential of metabolomics, the systems level study of small molecule metabolites, to help overcome these gaps and serve as a unique biochemical bridge between the phenotypic properties of chemical compounds and biological targets.